Empagliflozin treatment or downregulation of SGLT-2 expression significantly ameliorated peritoneal fibrosis by suppressing TGF-β/Smad signaling-associated proteins, such as TGF-β1 and phosphorylated Smad3 (p-Smad3)27. Here, SLC5A2 is linked to Peritoneal Fibrosis.